PATENT CLAIM ANALYSIS

Application Number: 15771379
Application Type: Utility
Filing Date: 2018-04
Publication Date: 2018-11
Patent Classification: ["514", "364000"]

Abstract:
Provided herein are methods of treating, preventing, ameliorating or managing a nonsense mutation mediated epileptic disease, comprising administering a 1,2,4-oxadiazole benzoic acid to a patient having a nonsense mutation mediated epileptic disease. In particular, provided herein are methods of treating, preventing, ameliorating or managing a CDKL5 and/or SCN1A (Dravet syndrome) nonsense mutation mediated epileptic disease.

Claim (Index 3):
The method of either of  claim 1  or  2 , wherein the salt is selected from the group consisting of a magnesium salt, a potassium salt, a sodium salt, a tromethamine salt, an L-lysine salt, an L-arginine salt, an N-methyl glucamine salt and an L-histidine salt.

Metadata:
- Claim Count in Document: 7.0
- Percentile: 91.0
- Lexical Diversity: 1.80556
- Patent Class: 514.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15961002', '10806899', '15449402', '15449535', '14881969']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7458574459634524
- 35 USC 102 Novelty (BERT): 0.5286896047262918
- Combined Prediction Score: 0.7241406618397364
- Mean Citation Score: 264.354614
- Max Citation Score: 283.49988
- Similarity Product: 125.8727570395696

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test